Literature DB >> 26826242

Autoreactive T Cells from Patients with Myasthenia Gravis Are Characterized by Elevated IL-17, IFN-γ, and GM-CSF and Diminished IL-10 Production.

Yonghao Cao1, Robert A Amezquita2, Steven H Kleinstein3, Panos Stathopoulos4, Richard J Nowak4, Kevin C O'Connor5.   

Abstract

Myasthenia gravis (MG) is a prototypical autoimmune disease that is among the few for which the target Ag and the pathogenic autoantibodies are clearly defined. The pathology of the disease is affected by autoantibodies directed toward the acetylcholine receptor (AChR). Mature, Ag-experienced B cells rely on the action of Th cells to produce these pathogenic Abs. The phenotype of the MG Ag-reactive T cell compartment is not well defined; thus, we sought to determine whether such cells exhibit both a proinflammatory and a pathogenic phenotype. A novel T cell library assay that affords multiparameter interrogation of rare Ag-reactive CD4(+) T cells was applied. Proliferation and cytokine production in response to both AChR and control Ags were measured from 3120 T cell libraries derived from 11 MG patients and paired healthy control subjects. The frequency of CCR6(+) memory T cells from MG patients proliferating in response to AChR-derived peptides was significantly higher than that of healthy control subjects. Production of both IFN-γ and IL-17, in response to AChR, was also restricted to the CCR6(+) memory T cell compartment in the MG cohort, indicating a proinflammatory phenotype. These T cells also included an elevated expression of GM-CSF and absence of IL-10 expression, indicating a proinflammatory and pathogenic phenotype. This component of the autoimmune response in MG is of particular importance when considering the durability of MG treatment strategies that eliminate B cells, because the autoreactive T cells could renew autoimmunity in the reconstituted B cell compartment with ensuing clinical manifestations.
Copyright © 2016 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26826242      PMCID: PMC4761502          DOI: 10.4049/jimmunol.1501339

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  66 in total

1.  Myasthenia gravis patients, but not healthy subjects, recognize epitopes that are unique to the epsilon-subunit of the acetylcholine receptor.

Authors:  Samia Ragheb; Mahmoud Mohamed; Robert P Lisak
Journal:  J Neuroimmunol       Date:  2004-11-23       Impact factor: 3.478

2.  Dysfunctional blood and target tissue CD4+CD25high regulatory T cells in psoriasis: mechanism underlying unrestrained pathogenic effector T cell proliferation.

Authors:  Hideaki Sugiyama; Rolland Gyulai; Eiko Toichi; Edina Garaczi; Shinji Shimada; Seth R Stevens; Thomas S McCormick; Kevin D Cooper
Journal:  J Immunol       Date:  2005-01-01       Impact factor: 5.422

Review 3.  T cells in multiple sclerosis and experimental autoimmune encephalomyelitis.

Authors:  J M Fletcher; S J Lalor; C M Sweeney; N Tubridy; K H G Mills
Journal:  Clin Exp Immunol       Date:  2010-10       Impact factor: 4.330

4.  Increased frequencies of myelin oligodendrocyte glycoprotein/MHC class II-binding CD4 cells in patients with multiple sclerosis.

Authors:  Khadir Raddassi; Sally C Kent; Junbao Yang; Kasia Bourcier; Elizabeth M Bradshaw; Vicki Seyfert-Margolis; Gerald T Nepom; William W Kwok; David A Hafler
Journal:  J Immunol       Date:  2011-06-08       Impact factor: 5.422

Review 5.  Myasthenia gravis: a comprehensive review of immune dysregulation and etiological mechanisms.

Authors:  Sonia Berrih-Aknin; Rozen Le Panse
Journal:  J Autoimmun       Date:  2014-01-03       Impact factor: 7.094

6.  Naturally occurring CD4+CD25+ regulatory T cells prevent but do not improve experimental myasthenia gravis.

Authors:  Valeria Nessi; Sara Nava; Chiara Ruocco; Chiara Toscani; Renato Mantegazza; Carlo Antozzi; Fulvio Baggi
Journal:  J Immunol       Date:  2010-09-29       Impact factor: 5.422

7.  Primary structure of the human muscle acetylcholine receptor. cDNA cloning of the gamma and epsilon subunits.

Authors:  D Beeson; M Brydson; M Betty; S Jeremiah; S Povey; A Vincent; J Newsom-Davis
Journal:  Eur J Biochem       Date:  1993-07-15

8.  Myasthenia gravis: passive transfer to mice of antibody to human and mouse acetylcholine receptor.

Authors:  K Oda; S Korenaga; Y Ito
Journal:  Neurology       Date:  1981-03       Impact factor: 9.910

9.  Evidence for an antigen-driven selection process in human autoantibodies against acetylcholine receptor.

Authors:  A Cardona; O Pritsch; G Dumas; J F Bach; G Dighiero
Journal:  Mol Immunol       Date:  1995-11       Impact factor: 4.407

10.  Clinical Features and Diagnostic Usefulness of Antibodies to Clustered Acetylcholine Receptors in the Diagnosis of Seronegative Myasthenia Gravis.

Authors:  Pedro M Rodríguez Cruz; Michal Al-Hajjar; Saif Huda; Leslie Jacobson; Mark Woodhall; Sandeep Jayawant; Camilla Buckley; David Hilton-Jones; David Beeson; Angela Vincent; Maria Isabel Leite; Jacqueline Palace
Journal:  JAMA Neurol       Date:  2015-06       Impact factor: 18.302

View more
  19 in total

1.  Relation of HLA-DRB1 to IgG4 autoantibody and cytokine production in muscle-specific tyrosine kinase myasthenia gravis (MuSK-MG).

Authors:  M Çebi; H Durmuş; V Yılmaz; S P Yentür; F Aysal; P Oflazer; Y Parman; F Deymeer; G Saruhan-Direskeneli
Journal:  Clin Exp Immunol       Date:  2019-04-12       Impact factor: 4.330

Review 2.  B cells in the pathophysiology of myasthenia gravis.

Authors:  John S Yi; Jeffrey T Guptill; Panos Stathopoulos; Richard J Nowak; Kevin C O'Connor
Journal:  Muscle Nerve       Date:  2017-09-30       Impact factor: 3.217

Review 3.  Antibody Therapies in Autoimmune Neuromuscular Junction Disorders: Approach to Myasthenic Crisis and Chronic Management.

Authors:  Fiammetta Vanoli; Renato Mantegazza
Journal:  Neurotherapeutics       Date:  2022-02-14       Impact factor: 6.088

4.  Inhibition of the transcription factor ROR-γ reduces pathogenic Th17 cells in acetylcholine receptor antibody positive myasthenia gravis.

Authors:  John S Yi; Melissa A Russo; Shruti Raja; Janice M Massey; Vern C Juel; Jay Shin; Lisa D Hobson-Webb; Karissa Gable; Jeffrey T Guptill
Journal:  Exp Neurol       Date:  2019-12-12       Impact factor: 5.330

5.  Essential role for CCR6 in certain inflammatory diseases demonstrated using specific antagonist and knockin mice.

Authors:  Remy Robert; Caroline Ang; Guizhi Sun; Laurent Juglair; Ee X Lim; Linda J Mason; Natalie L Payne; Claude Ca Bernard; Charles R Mackay
Journal:  JCI Insight       Date:  2017-08-03

Review 6.  Advances in autoimmune myasthenia gravis management.

Authors:  Shuhui Wang; Iva Breskovska; Shreya Gandhy; Anna Rostedt Punga; Jeffery T Guptill; Henry J Kaminski
Journal:  Expert Rev Neurother       Date:  2018-07-04       Impact factor: 4.618

7.  Single-cell profiling of myasthenia gravis identifies a pathogenic T cell signature.

Authors:  Bettina Schreiner; Burkhard Becher; Florian Ingelfinger; Sinduya Krishnarajah; Michael Kramer; Sebastian G Utz; Edoardo Galli; Mirjam Lutz; Pascale Zwicky; Ayse U Akarca; Nicole Puertas Jurado; Can Ulutekin; David Bamert; Corinne C Widmer; Luca Piccoli; Federica Sallusto; Nicolás G Núñez; Teresa Marafioti; Didier Schneiter; Isabelle Opitz; Antonio Lanzavecchia; Hans H Jung; Donatella De Feo; Sarah Mundt
Journal:  Acta Neuropathol       Date:  2021-03-28       Impact factor: 17.088

Review 8.  Roles of cytokines and T cells in the pathogenesis of myasthenia gravis.

Authors:  A Uzawa; S Kuwabara; S Suzuki; T Imai; H Murai; Y Ozawa; M Yasuda; Y Nagane; K Utsugisawa
Journal:  Clin Exp Immunol       Date:  2020-12-03       Impact factor: 5.732

9.  CD4+ T Cells of Myasthenia Gravis Patients Are Characterized by Increased IL-21, IL-4, and IL-17A Productions and Higher Presence of PD-1 and ICOS.

Authors:  Merve Çebi; Hacer Durmus; Fikret Aysal; Berker Özkan; Gizem Engin Gül; Arman Çakar; Mehmet Hocaoglu; Metin Mercan; Sibel P Yentür; Melih Tütüncü; Vildan Yayla; Onur Akan; Öner Dogan; Yeşim Parman; Güher Saruhan-Direskeneli
Journal:  Front Immunol       Date:  2020-05-19       Impact factor: 7.561

Review 10.  Short- and Long-Lived Autoantibody-Secreting Cells in Autoimmune Neurological Disorders.

Authors:  C Zografou; A G Vakrakou; P Stathopoulos
Journal:  Front Immunol       Date:  2021-06-17       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.